Close

Roth Capital Downgrades Galectin Therapeutics (GALT) to Sell

Go back to Roth Capital Downgrades Galectin Therapeutics (GALT) to Sell

H.C. Wainwright Downgrades Galectin Therapeutics (GALT) to Neutral

September 29, 2016 7:06 AM EDT

H.C. Wainwright downgraded Galectin Therapeutics (NASDAQ: GALT) from Buy to Neutral with a price target of $1.50 (from $8.00) after the company reported that the Phase 2 NASH-FX trial missed its primary endpoint, improvement in liver fibrosis measured by cT1 (LiverMultiScan), as well as both secondary endpoints, liver stiffness (a surrogate for fibrosis) as measured by magnetic resonance elastography (MRE) and FibroScan.

Analyst Ed Arce commented, "This unequivocal... More

Galectin Therapeutics (GALT) Agrees to Sell 1.5M Convertible Preferred Shares

September 27, 2016 4:18 PM EDT

Galectin Therapeutics (NASDAQ: GALT) disclosed that on September 22, 2016 it entered into a Securities Purchase Agreement with 10X Fund, L.P., a Delaware limited partnership (Purchaser). Pursuant to the Purchase Agreement, the Company has agreed to issue and sell to Purchaser, and Purchaser has agreed to purchase from the Company at closings held or to be held on September 22, 2016 and September 29, 2016 (i)... More